DKK625.50
2.04% today
Copenhagen, Sep 25, 12:36 pm CET
ISIN
DK0060055861
Symbol
CHEMM

ChemoMetec Target price 2025 - Analyst rating & recommendation

ChemoMetec Classifications & Recommendation:

Buy
91%
Hold
9%

ChemoMetec Price Target

Target Price DKK652.80
Price DKK638.50
Potential
Number of Estimates 6
6 Analysts have issued a price target ChemoMetec 2026 . The average ChemoMetec target price is DKK652.80. This is higher than the current stock price. The highest price target is
DKK714.00 11.82%
register free of charge
, the lowest is
DKK555.50 13.00%
register free of charge
.
A rating was issued by 11 analysts: 10 Analysts recommend ChemoMetec to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the ChemoMetec stock has an average upside potential 2026 of . Most analysts recommend the ChemoMetec stock at Purchase.

Sales and Margin forecast 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Jun '25 2026
Estimates
Revenue Million DKK 495.57 580.41
21.50% 17.12%
EBITDA Margin 54.45% 58.12%
19.29% 6.74%
Net Margin 37.62% 45.31%
12.58% 20.46%

5 Analysts have issued a sales forecast ChemoMetec 2026 . The average ChemoMetec sales estimate is

DKK580m
Unlock
. This is
17.12% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
DKK609m 22.89%
Unlock
, the lowest is
DKK536m 8.17%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 DKK496m 21.50%
2026
DKK580m 17.12%
Unlock
2027
DKK671m 15.62%
Unlock

5 Analysts have issued an ChemoMetec EBITDA forecast 2026. The average ChemoMetec EBITDA estimate is

DKK337m
Unlock
. This is
30.72% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
DKK363m 40.79%
Unlock
, the lowest is
DKK303m 17.35%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 DKK270m 44.94%
2026
DKK337m 25.01%
Unlock
2027
DKK366m 8.55%
Unlock

EBITDA Margin

2025 54.45% 19.29%
2026
58.12% 6.74%
Unlock
2027
54.57% 6.11%
Unlock

5 ChemoMetec Analysts have issued a net profit forecast 2026. The average ChemoMetec net profit estimate is

DKK263m
Unlock
. This is
41.09% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
DKK296m 58.77%
Unlock
, the lowest is
DKK224m 20.29%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 DKK186m 36.78%
2026
DKK263m 41.09%
Unlock
2027
DKK307m 16.73%
Unlock

Net Margin

2025 37.62% 12.58%
2026
45.31% 20.46%
Unlock
2027
45.75% 0.97%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Jun '25 2026
Estimates
Earnings Per Share DKK 10.71 15.12
36.78% 41.18%
P/E 42.24
EV/Sales 18.76

5 Analysts have issued a ChemoMetec forecast for earnings per share. The average ChemoMetec EPS is

DKK15.12
Unlock
. This is
41.18% higher
Unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
DKK17.01 58.82%
Unlock
, the lowest is
DKK12.89 20.35%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 DKK10.71 36.78%
2026
DKK15.12 41.18%
Unlock
2027
DKK17.64 16.67%
Unlock

P/E ratio

Current 59.62 8.56%
2026
42.24 29.15%
Unlock
2027
36.19 14.32%
Unlock

Based on analysts' sales estimates for 2026, the ChemoMetec stock is valued at an EV/Sales of

18.76
Unlock
and an P/S ratio of
19.34
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 21.97 24.62%
2026
18.76 14.61%
Unlock
2027
16.23 13.51%
Unlock

P/S ratio

Current 22.65 23.45%
2026
19.34 14.62%
Unlock
2027
16.73 13.51%
Unlock

Current ChemoMetec Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
DNB CARNEGIE
Locked
Locked
Locked May 08 2025
DNB CARNEGIE
Locked
Locked
Locked May 07 2025
DNB MARKETS
Locked
Locked
Locked Feb 05 2025
DNB MARKETS
Locked
Locked
Locked Nov 10 2024
Analyst Rating Date
Locked
DNB CARNEGIE:
Locked
Locked
May 08 2025
Locked
DNB CARNEGIE:
Locked
Locked
May 07 2025
Locked
DNB MARKETS:
Locked
Locked
Feb 05 2025
Locked
DNB MARKETS:
Locked
Locked
Nov 10 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today